对于阿尔茨海默氏症评估而言,合成到现实的专注深度学习:ROCF评分的域异构框架
Kassem Anis Bouali1, Elena Šikudová1
1Department of Software and Computer Science Education, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic.
Journal of biomedical informatics
|October 19, 2025
概括
这项研究引入了使用合成数据和专门的深度学习模型对雷-奥斯特里斯复杂图 (ROCF) 测试进行自动评分的新框架,改进了阿尔茨海默病诊断. 这种方法提高了准确性,并减少了认知评估中的偏见.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 早期阿尔茨海默病的诊断依赖于认知测试,如雷-奥斯特里斯复杂图 (ROCF).
- 手动ROCF评分是耗时的,主观的,容易产生偏见.
- 有限的注释临床数据阻碍了深度学习模型的开发和ROCF分析的概括.
研究的目的:
- 开发一种使用合成数据自动化ROCF评分的新框架.
- 为了解决有限数据和领域转移在认知评估的深度学习模型的挑战.
- 提高阿尔茨海默病诊断ROCF评分的准确性,效率和公平性.
主要方法:
- 一个轻量级的数据合成管道,生成多样化的,注释的ROCF图纸.
- ROCF-Net是一个深度学习模型,旨在跨域ROCF评分,解决纹理和线条文物变化.
- 在ROCF-Net中创建了一种新的线路特定注意力机制,以提高得分准确度.
主要成果:
- 该框架生成现实的ROCF图纸,有效地反映阿尔茨海默氏症的异常.
- 在各种数据集中,ROCF-Net实现了最先进的性能 (MAE 3.53,PCC 0.86).
- 在合成数据上训练的模型表现出与在真实临床数据上训练的模型相似的概括,性能差异最小.
结论:
- 引入了一个成本效益高的合成ROCF数据生成管道.
- 开发了一个自动化ROCF评分的域异性模型.
- 集成了一个轻量级的注意力机制,以实现透明的临床评分对齐.
- 提出了一个使用合成数据的偏见意识框架,以减轻认知评估中的人口差异.
更多相关视频
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.7K
09:13A Fully Automated and Highly Versatile System for Testing Multi-cognitive Functions and Recording Neuronal Activities in Rodents
Published on: May 3, 2012
14.8K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
